Literature DB >> 17100976

A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis.

Steven R Brant1, Ming-Hsi Wang, Patricia Rawsthorne, Michael Sargent, Lisa Wu Datta, Franklin Nouvet, Yin Yao Shugart, Charles N Bernstein.   

Abstract

OBJECTIVES: Multiple established Crohn's disease (CD) and ulcerative colitis (UC) risk factors including family history, tobacco use, Jewish ethnicity, urban residency, and CARD15/NOD2 mutations have been evaluated singly and in hospital-based observational studies. The goal of this study was to assess the relative contributions of all these risk factors jointly in a nonreferral, population-based cohort derived from a population epidemiologic database.
METHODS: CD (N = 232) and UC (N = 121) subjects were ascertained from our population-based IBD Registry derived from Manitoba Health, the single provincial insurer. Healthy controls (HC) (N = 336) were recruited via a 10:1 mailing matched for age, sex, and postal code. Ethnicity, tobacco use, family history, residency, and CARD15/NOD2 genotype status were determined.
RESULTS: In both univariate analyses and analyses adjusted for all risk factors, CD was influenced independently by CARD15/NOD2 heterozygote and homozygote/compound-heterozygote status (adjusted odds ratios [OR] 3.7 and 40.0, respectively), Jewish ethnicity (OR 18.5), CD family history (OR 6.2), and smoking (OR 3.0 current and 1.7 ex-smoker, respectively). Penetrance for homozygote/compound-heterozygotes was 4.9%, heterozygotes 0.54%, and wild types 0.184%. Population attributable risk for CARD15 was 26.7% and current tobacco use was 46.8%. A tobacco-CARD15 interaction was not observed. UC was influenced by Jewish ethnicity (OR 37.1), and by family history (OR 2.6), ex-smoker status (OR 1.9), and CARD15/NOD2 heterozygote or homozygote/compound-heterozygote status (OR 1.9 and 6.4, respectively) in adjusted analyses only.
CONCLUSIONS: CARD15/NOD2, family history, smoking, and Jewish ethnicity are independent risk factors for CD. Examination of these risk factors together in a single population-based cohort has provided initial data for population epidemiological characterization and genetic counseling uses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100976     DOI: 10.1111/j.1572-0241.2006.00926.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  26 in total

1.  Smoking and inflammatory bowel diseases: what in smoking alters the course?

Authors:  A M El-Tawil
Journal:  Int J Colorectal Dis       Date:  2010-03-24       Impact factor: 2.571

2.  Measurement of Fractional Exhaled Nitric Oxide as a Marker of Disease Activity in Inflammatory Bowel Disease.

Authors:  Erkanda Ikonomi; Robin D Rothstein; Adam C Ehrlich; Frank K Friedenberg
Journal:  J Gastroenterol Pancreatol Liver Disord       Date:  2016-01-27

3.  Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease.

Authors:  Charles N Bernstein; Ming-Hsi Wang; Michael Sargent; Steven R Brant; Michael T Collins
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

Review 4.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

5.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

6.  Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch.

Authors:  Bo Shen; Feza H Remzi; Jeffrey P Hammel; Bret A Lashner; Charles L Bevins; Ian C Lavery; Jan Wehkamp; Victor W Fazio
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

Review 7.  The impact of smoking in Crohn's disease: no smoke without fire.

Authors:  Marian C Aldhous; J Satsangi
Journal:  Frontline Gastroenterol       Date:  2010-09-23

Review 8.  Role of genetics in pediatric rheumatology.

Authors:  Eda Tahir Turanlı; Elif Everest; Ayşe Balamir; Aslı Kireçtepe Aydın; Özgür Kasapçopur
Journal:  Turk Pediatri Ars       Date:  2017-09-01

Review 9.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

10.  NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans.

Authors:  Themistocles Dassopoulos; Geoffrey C Nguyen; Monica Vladut Talor; Lisa Wu Datta; Kim L Isaacs; James D Lewis; Michael S Gold; John F Valentine; Duane T Smoot; Mary L Harris; Maria Oliva-Hemker; Theodore M Bayless; C Lynne Burek; Steven R Brant
Journal:  Am J Gastroenterol       Date:  2009-10-13       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.